NewAmsterdam Pharma Company (NASDAQ:NAMS) has been granted a new patent by the United States Patent and Trademark Office.

The patent, which extends protection for obicetrapib until July 2043, covers the amorphous form of the drug compound.

Michael Davidson, NewAmsterdam’s Chief Executive Officer, noted, “There continues to be a need for a safe, efficacious, oral, and potent LDL-lowering therapy.”

The new patent marks the third-generation protective rights for the drug, adding over nine years of exclusivity beyond previous patents.